Increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market.
The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period.

The global Liquid Biopsy market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Liquid Biopsy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Liquid Biopsy market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Liquid Biopsy in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Liquid Biopsy manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Biocept
Qiagen
Roche Diagnostics
Bio-Rad Laboratories
Myriad Genetics
Menarini-Silicon Biosystems
Trovagene
Guardant Health
Mdxhealth
Genomic Health
Raindance Technologies
Thermo Fisher Scientific
Illumina

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Test Suite
Equipment
Service

Segment by Application
Reference Laboratory
The Hospital
Research Center
Other